top of page

Our news

Screenshot 2024-11-26 at 12.00.11.png
kyron.bio today announced a €5.5M Seed Round

The seed funding round was led by HCVC, with the participation of Verve Ventures, Entrepreneur First, Saras Capital, and numerous reputable angel investors.
The funds will accelerate the development of kyron.bio’s proprietary glycan-engineering platform, expand the kyron.bio team and fuel preclinical studies.

2025

Screenshot 2024-11-26 at 12.00.11.png
kyron.bio selected as Deep Tech Pioneer

kyron.bio is proud to have been selected as Deep Tech Pioneer by Hello Tomorrow out of thousands of applicants! This recognition puts our technology at the forefront of game-changing deep-tech solutions. We’re looking forward to attend the Hello Tomorrow Global Summit, March 2025, and connect with the world’s top innovators, industry leaders and investors.

2024

Screenshot 2024-11-26 at 12.00.11.png
kyron.bio Relocates to Paris Biotech Santé at Hôpital Cochin

kyron.bio is thrilled to announce our relocation to Hôpital Cochin, where we are now part of Paris Biotech Santé, the leading healthtech incubator in Paris. This move not only places us at the heart of a thriving biotech ecosystem but also provides expanded lab space, enabling us to accelerate our R&D efforts and pursue new scientific avenues.

2025

Screenshot 2024-11-26 at 12.00.11.png
kyron.bio attends PEGS 2024

kyron.bio attends the PEGS Europe 2024 conference in Barcelona, alongside 1500+ protein & antibody engineering innovators! Our R&D lead, Marina Lochhead attends, having this opportunity to connect with top experts in the field, staying at the forefront of emerging trends and engaging in trailblazing discussions.

2024

Screenshot 2024-11-26 at 12.00.11.png
kyron.bio awarded 2025 EIC Transition

kyron.bio is awarded a €2.5M EIC Transition grant, a highly competitive European grant awarded to technologies that are ready to make the leap from the lab to the market. The grant was awarded to kyron.bio and their consortium partner, Genos Glyco, after the highest number of applicants on record. This award highlights the European Union’s recognition of the innovative potential of glycan engineering to create safer and more effective therapies for patients.

2025

Screenshot 2024-11-26 at 12.00.11.png
kyron.bio attends Bio-Europe 2024

kyron.bio is excited to be attending Bio-Europe 2024, a global partnering conference where the world’s lifescience ecosystem meets to propel dealmaking and innovation. Our CEO will be joining some of the biggest names in the game in Stockholm, and is looking forward to connect, exchange insights, and explore potential collaborations!

2024

kyron.bio in the news

Maddyness

Kyron.bio veut développer des médicaments pour lutter contre les cancers

BioPharm International

Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics

Forbes

Meet The Biotech Innovator Flying The Flag For Europe’s Women Founders

European Medical Journal

Kyron.bio lands €5.5m to refine biologic drug design

French Web

Kyron.bio lève 5,5 millions d’euros pour industrialiser la glyco-ingénierie thérapeutique

Forbes

Classement : le top 10 des plus grandes levées de fonds de la French Tech en mai 2025

EU-Startups

Paris-based kyron.bio secures €5.5 million to tackle drug efficiency and safety

Silicon Canals

French female-led biotech kyron.bio raises €5.5M to tackle a major challenge in biologic drug development using sugar molecules

bottom of page